July 9, 2025 07:07 AM EDT
R&D
Cell/Gene Tx

As­traZeneca’s Alex­ion inks AAV cap­sid deal with JCR Phar­ma

Anna Brown

News Reporter

As­traZeneca’s rare dis­ease busi­ness Alex­ion re­turns to JCR Phar­ma­ceu­ti­cals for an­oth­er deal, this time for a pact worth up to $825 mil­lion for its ade­no …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Mer­ck drops $10B for res­pi­ra­to­ry drug­mak­er Verona Phar­ma in its first ac­qui­si­tion of 2025

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Bio­phar­ma's 20 high­est-paid CEOs of 2024 with $20M+ pay­days

FDA ap­proves new dos­ing of Lil­ly’s Alzheimer’s drug to low­er brain swelling risks

Nim­ble ra­dio­phar­ma biotech Ac­tithera gets $75M to en­ter the clin­ic

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times